• Human APIs PowderRespiratory Drugs Raw Material Antiviral Antibacterial Antipyretic Analgesics Antihistamine Drugs Antineoplastic Cosmetic Raw Material
  • Pharmaceutical IntermediatesPharmaceutical intermediates Nutritional Supplements Pharmaceutical raw materials
  • OEM & ODMCapsule Softgel Capsule Gummies Drop & drinks Tables
  • Veterinary raw materialsAntibacterial anti-inflammatory Respiratory Drugs Anthelmintics Antiviral drugs Feed additives
  • About UsCompany profileQualificationQuality AssuranceService teamFactory TourR&D Center
  • Paracetamol Aspirin Raw Materials Powder

    • Paracetamol Aspirin Raw Materials Powder
    • Paracetamol Aspirin Raw Materials Powder storehouse
    • Paracetamol Aspirin Raw Materials Powder quality testing
    • Paracetamol Aspirin Raw Materials Powder quality testing
    • Paracetamol Aspirin Raw Materials Powder certificate

    Product Overview:

    Candesartan ester is the precursor drug of Candesartan, the intensity of action is 10 times that of Losartan, the selectivity of action is good (the affinity of AT1 receptor is more than 10000 times higher than that of AT2), and the action time is long (1 time per day), due to the precursor drug orally after the release of the active role of the body is relatively calm, so it is the ideal drug for the treatment of high blood pressure.

    Paracetamol Aspirin Raw Materials Powder Attributes

    Paracetamol  Candesartan Cilexetil (C11)  Raw Materials Powder

    CAS:145040-37-5

    MF: C33H34N6O6

    Candesartan Cilexetil (C11)  Raw Powder

    MW: 610.66

    EINECS:627-030-2

    Specification​: 99% min  Candesartan Cilexetil (C11)  Powder

    Sample:  Candesartan Cilexetil (C11)  Powder

    Packaging:1kg/bag, 25kg/drum

    Brand: Henrikang

    Appearance: White Powder

    Storage: Cool Dry Place

    Shelf Life: 2 Years

    Test Method: HPLC

    Paracetamol Aspirin Raw Materials Powder Details

    Candesartan Cilexetil (C11)  Powder Usage and Synthesis.

    Candesartan ester is the precursor of candesartan, which is rapidly and completely hydrolysed to candesartan during gastrointestinal absorption.The absolute bioavailability of candesartan is about 15%, and the peak time of plasma candesartan concentration is 3-4 hours.

    The binding rate of candesartan to plasma proteins is greater than 99%, and the apparent volume of distribution is 0.13 L/kg. Rat tests have demonstrated that candesartan rarely crosses the blood-brain barrier, but can cross the placental barrier and be distributed to the foetus.

    Candesartan is excreted mainly in its original form in the urine and faeces, with a very small portion in the liver via O-deethylation to form inactive metabolites. The excretion half-life of candesartan is approximately 9 hours.

    In hypertensive patients receiving 2-16 mg/day of the product orally for 4 weeks, the plasma clearance of candesartan was 14.07 L/h and the terminal elimination half-life was 9-13 hours.

    It has been shown that the total clearance of candesartan is 0.37 ml/min-kg, renal clearance is 0.19 mL, and after oral administration of 14C-labelled candesartan ester, 33% and 67% of the radioactivity is recovered in urine and faeces, respectively.

    Candesartan Cilexetil (C11)  Powder

    Uses and functions of  Candesartan Cilexetil (C11) .

    Candesartan is a antihypertensive agent. It is a selective angiotensin I receptor (ATI) antagonist. By binding to ATI receptor of vascular smooth muscle, Candesartan inhibits vasoconstriction of angiotensin II, thereby reducing peripheral vascular resistance. It is mainly used to treat essential hypertension and can be used alone or in combination with other antihypertensive drugs.

    Candesartan Cilexetil (C11)  Raw Powder

    Pharmacological Effects of  Candesartan Cilexetil (C11) .

    Candesartan ester is rapidly hydrolysed in vivo to the active metabolite candesartan, which is a selective angiotensin II receptor (AT1) antagonist, antagonising the vasoconstrictor effect of angiotensin II by binding to the AT1 receptor in vascular smooth muscle, thereby reducing peripheral vascular resistance.

    It is also believed that Candesartan may exert some antihypertensive effects by inhibiting the secretion of aldosterone from the adrenal glands. Candesartan does not inhibit kininase II and does not affect bradykinin degradation.

    Experiments conducted in hypertensive patients have shown that repeated administration of this product to patients can lead to an increase in plasma renin activity, angiotensin 1 concentration and angiotensin II concentration;

    The continuous administration of 2-8mg of this product once a day can lead to a decrease in systolic and diastolic blood pressure, a decrease in left ventricular myocardial weight and peripheral vascular resistance, while there is no significant effect on cardiac output, ejection fraction, renal vascular resistance, renal blood flow and glomerular filtration rate; there is no effect on cerebral blood flow in patients with proto-genital hypertension who have cerebral vascular disorders.

    Candesartan Cilexetil (C11)  Raw Materials

    Production method of  Candesartan Cilexetil (C11)  Raw Powder.

    Oral, usually 4 to 8mg candesartan cilostatin once a day for adults, increase the dose to 12mg if necessary.

    Our advantage
    Our Factory
    Shipping
    Tel: 86-29-89601602
    WhatsApp: 8615091775531
    WeChat: 15091775531
    E-mail: sales21@interlgroup.com
    Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
    ©2023 Xi'an Henrikang Biotech Co., Ltd.,